


Rating	STRONG BUY
Price	₩9.12
FVE	<del>N</del> 5.30
52-week range	<del>N</del> 4.35-9.65
Market Cap. (₦'bn)	190,245
l-month Avg. Vol	14,352,359
Curr. PB	0.32x



Oluwasegun Akinwale Oluwasegun.akinwale@arm.com.ng

# FBN Holdings Plc. (FBNH.NL)

#### Initial View

### Further improvement in asset quality

- FBN Holdings Plc (FBNH) released unaudited 9M 19 result after close of trading yesterday, recording PBT and PAT growth of 17% YoY and 15% YoY respectively, both coming ahead of our estimates. While both net interest income (-5% YoY) and non-interest revenue (+6% YoY) represents 74% and 73% of our full year estimate, the deviation stemmed from materially lower loan loss provision relative to our estimates. Reported loan credit loss provision is down 63% YoY, with related cost of risk contracting 338bps to 1.9%. Interestingly, asset quality improved further to 12.6% from 14.5% at the end of H1 19. In absolute terms, NPL declined by N29 billion to N244 billion, reflecting cumulative write-off of N25 billion over Q3 19 by our estimate. Going by the run rate, we believe management is set to achieve its single digit NPL by the end of the year.
- On the income lines, the bank recorded moderation in annualized NIM by 56bps YoY following faster decline in assets yield (-66bps YoY) compared to WACF (-25bps YoY). While loan yield improved 29bps YoY, yield on investment securities declined 132bps YoY by our estimate. On funding cost, the moderation stemmed from decline in deposits cost by 27bps following improvement in CASA proportion of deposits to 78% from 70% in 9M 18. Also, following the early redemption of its \$450 million Eurobond in July, borrowing cost declined 346 bps YoY. Elsewhere, NIR remained resilient, expanding 6% YoY due to higher net fee and insurance income, gains on securities trading and other income.
- Streamlining to the quarterly numbers, while PBT moderated 2% QoQ, a lower effective tax pushed PAT higher by 26% QoQ. Key surprises for us during the quarter is the jump in interest expense (+10% QoQ), which was further aggravated by a decline in interest income (-4% QoQ). As a result, annualised NIM contracted 84bps QoQ. Non-interest revenue on the other end, came in higher (6% QoQ), reflective of strong gains on net fee income and stronger performance on the other income lines. Another positive, is the decline in provisioning (23% QoQ), with cost of risk 24bps lower QoQ to 1%.
- Our last communicated FVE of **N9.12**, translates to a STRONG BUY recommendation on our rating scale. Given that the results released so far this year is unaudited, key risks to our expectation is a more aggressive write-off over Q4 19 than the last three quarters.

9M 2019 analyst and investors conference call: FBNH would be hosting a conference call on 25
October at 15.00 Lagos & London time. For more details, <u>click here</u>

## **Summary of Results**

N'million	9M 19	9M 18	YoY (pps)	Q3 19	Q2 19	QoQ
Gross Earnings	426,238	430,759	-1.0%	140,926	143,104	-1.5%
Net Interest Income	211,438	221,526	-4.6%	64,721	72,536	-10.8%
Non-Interest Revenue	98,769	93,201	6.0%	35,237	33,373	5.6%
Operating Expenses	(221,735)	(187,235)	18.4%	(73,443)	(77,103)	-4.7%
Impairment	(28,460)	(76,185)	-62.6%	(6,353)	(8,260)	-23.1%
РВТ	60,029	51,340	16.9%	20,162	20,563	-2.0%
РАТ	51,836	449,470	-88.5%	20,123	15,921	26.4%
EPS	1.44	1.25	15.3%	0.56	0.44	26.4%
N'million	9M 19	<b>9M 18</b>	YoY (pps)	Q2 19	QoQ	
Loans	1,819,654	1,924,540	-5.4%	1,743,232	4.4%	
Total Assets	5,734,484	5,347,976	7.2%	5,670,246	1.1%	
Deposits	3,671,052	3,383,695	8.5%	3,582,605	2.5%	
Total Liabilities	5,129,557	4,652,363	10.3%	5,109,329	0.4%	
Net Assets	604,927	695,613	-13.0%	560,917	7.8%	
BVPS	16.85	19.38	-13.0%	15.63	7.8%	
	9M 19	9M 18	change (pps)	Q3 19	Q2 19	change (pps)
Assets Yields	12.5%	13.2%	(0.7)	12.1%	12.5%	(0.4)
WACF	3.3%	3.6%	(0.2)	3.5%	3.2%	0.3
Net Interest Margin	8.1%	8.6%	(0.6)	7.4%	8.3%	(0.8)
Cost-Income Ratio	71.5%	59.5%	12.0	73.5%	72.8%	0.7
Cost of Risk	2.1%	5.3%	(3.2)	1.0%	1.2%	(0.2)
ROE	11.4%	8.6%	2.8	13.8%	11.5%	2.3
CAR	15.0%	17.4%	(2.4)	15.0%	15.6%	(0.6)

#### **ARM ratings and recommendations**

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for rating subject to target price deviation is outlined below:

<b>TOP 20</b>		NON-TOP 20	
Rating	Deviation	Rating	Deviation
STRONG BUY	>20%	BUY	>20%
OVERWEIGHT	10% 20 %	NEUTRAL	5% - 20%
NEUTRAL	0% 10 %	SELL	<5%
UNDERWEIGHT	-5% - 0%		
SELL	<-5%		

RECOMMENDATION KEY		
Rating	Recommendation	
BUY	Accumulate security to a substantial extent constrained only by portfolio diversification considerations	
OVERWEIGHT	Accumulate security to an extent moderated by cognizance of its benchmark weight	
NEUTRAL	Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reas portfolio constraints	
UNDERWEIGHT	Minimize exposure to security taking cognizance of its index weighting	
SELL	Sell-off security completely from portfolio	

Copyright © 2019 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.